MESSAGE/INFORMATION

Date
12 February 2015

Our reference
452-H15-00138

Development of Legislation and Other Instruments
Mary Iakovidou

ECHA
Erik van de Plassche
Biocidal Products Committee

BPC-9: Minority opinion on the proposal for approval of reaction mass of 5-chloro-2-methyl-2h-isothiazol-3-one and 2-methyl-2h-isothiazol-3-one (3:1) (CMIT/MIT) in PT6

The Swedish Competent Authority notes the potent sensitising effect of CMIT/MIT and proposes that the forthcoming opinion of the Biocidal Products Committee (BPC) on CMIT/MIT should identify CMIT/MIT in PT 6 as a candidate substance for substitution in accordance with Article 10(1)(e) of the Biocidal Products Regulation (EU) No. 528/2012 (BPR).

CMIT/MIT is a very potent sensitizer to which a proportion of the population is already sensitised. The concern is not only the number of new cases of sensitized individuals but also the increasing reports of elicitation from secondary exposure to the preservative. We consider that the use of CMIT/MIT in biocidal products should be limited as far as possible, especially where exposure is not minimized by, for example, automated processes. We understand from comments supplied so far by stakeholder representatives that it may not be possible to substitute CMIT/MIT completely but substitution should be applied where it is possible. We therefore consider it appropriate for CMIT/MIT in PT 6 to be identified as a candidate for substitution.

Use in PT 6 results in exposure to the general public both to preparations that are preserved and to the objects to which those preparations are applied.

We agree with the CA meeting’s position that criterion (e) of Article 10(1) should be applied sparingly, in exceptional circumstances but we consider that the approval of CMIT/MIT in PT 6 is particularly appropriate case since the other provisions of the BPR, for example paragraph 66 of Annex VI, will not be sufficient to maintain a high level of protection for humans.

Yours sincerely

Mary Iakovidou